2026 ASCO Genitourinary Cancers Symposium
Trials whose public commentary places their results at 2026 ASCO Genitourinary Cancers Symposium, Feb 26–28, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
12 trials: 0 with reports and 12 with no report yet. Organised by American Society of Clinical Oncology (ASCO); cosponsored by ASTRO and SUO; Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
No published report on a trial placed at 2026 ASCO Genitourinary Cancers Symposium yet.
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Prostate cancer · 4 | |||||||
| BRCAAway olaparib plus abiraterone; olaparib placed at 2026 ASCO Genitourinary Cancers Symposium by 20 sources NCT03012321 · Northwestern University DeepView → | metastatic castration-resistant prostate cancer with DNA repair defects | Phase 2 | Deep | View | |||
| GUNS apalutamide; apalutamide plus abiraterone; abiraterone plus docetaxel placed at 2026 ASCO Genitourinary Cancers Symposium by 5 sources NCT04812366 · University of British Columbia DeepView → | high-risk localized prostate cancer | Phase 2 | Deep | View | |||
| ARASENS darolutamide placed at 2026 ASCO Genitourinary Cancers Symposium by 3 sources NCT02799602 · Bayer DeepView → | metastatic hormone-sensitive prostate cancer | Phase 3 | Deep | View | |||
| ENZAMET enzalutamide placed at 2026 ASCO Genitourinary Cancers Symposium by 2 sources NCT02446405 · University of Sydney DeepView → | metastatic hormone-sensitive prostate cancer | Phase 3 | Deep | View | |||
| Renal cell carcinoma · 3 | |||||||
| LITESPARK-022 belzutifan plus pembrolizumab placed at 2026 ASCO Genitourinary Cancers Symposium by 23 sources NCT05239728 · Merck Sharp & Dohme LLC DeepView → | adjuvant clear cell renal cell carcinoma post nephrectomy | Phase 3 | Deep | View | |||
| CYTOSHRINK Drug not named yet placed at 2026 ASCO Genitourinary Cancers Symposium by 3 sources NCT04090710 · Ontario Clinical Oncology Group (OCOG) DeepView → | metastatic renal cell carcinoma | Phase 2 | Deep | View | |||
| RAMPART durvalumab; durvalumab plus tremelimumab placed at 2026 ASCO Genitourinary Cancers Symposium by 2 sources NCT03288532 · University College, London DeepView → | intermediate- or high-risk resected renal cell carcinoma | Phase 3 | Deep | View | |||
| Urothelial carcinoma · 5 | |||||||
| KEYNOTE-B15 enfortumab vedotin plus pembrolizumab placed at 2026 ASCO Genitourinary Cancers Symposium by 29 sources NCT04700124 · Merck Sharp & Dohme LLC DeepView → | cisplatin-eligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| SunRISe-2 TAR-200 plus cetrelimab placed at 2026 ASCO Genitourinary Cancers Symposium by 10 sources NCT04658862 · Janssen Research & Development, LLC DeepView → | muscle-invasive urothelial carcinoma of the bladder | Phase 3 | Deep | View | |||
| KEYNOTE-905 enfortumab vedotin plus pembrolizumab; pembrolizumab placed at 2026 ASCO Genitourinary Cancers Symposium by 9 sources NCT03924895 · Merck Sharp & Dohme LLC DeepView → | cisplatin-ineligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYMAKER-U04 MK-4280A plus enfortumab vedotin; MK-7684A plus enfortumab vedotin placed at 2026 ASCO Genitourinary Cancers Symposium by 3 sources NCT05845814 · Merck Sharp & Dohme LLC StandardView → | first-line metastatic urothelial carcinoma | Phase 1/Phase 2 | Standard | View | |||
| INDIBLADE ipilimumab plus nivolumab placed at 2026 ASCO Genitourinary Cancers Symposium by 2 sources NCT05200988 · The Netherlands Cancer Institute DeepView → | muscle-invasive bladder cancer | Phase 2 | Deep | View | |||